Entries by mpp-yoshida

Legionella pneumophila

Legionella pneumophila is a type of bacteria that inhabits natural environments as soil, rivers and water bodies, and infection typically occurs through inhalation of water vapor or aerosols. It proliferates in poor sanitary conditions of water circulation systems such as humidifiers, hot tubs (sauna).

Bacillus subtilis

Bacillus subtilis is generalist in nature, including dead grass and soil. It is recognized as a safe bacterium with no reported pathogenic effects on humans.

Salmonella enteritidis

Salmonella is a bacterium that is widely found in nature, including humans, in the intestines of livestock, and in rivers. It is well known as a cause of food poisoning, causing symptoms such as diarrhea and nausea.

Klebsiella pneumoniae

Klebsiella pneumoniae is a Gram-negative bacterium typically a part of the human enterobacteria. It is a major pathogen of respiratory and urinary tract infections, and can also cause bacteremia and sepsis.

opportunistic infection

An infection that occurs more frequently or severe in patients with weakened immune systems, such as patients receiving chemotherapy and patients with blood disorders than in people with healthy immune systems.

Staphylococcus aureus

Staphylococcus aureus is a bacterium that lives on the skin and mucous membranes in many people. It can also cause skin infections and food poisoning.In case of a compromised immune system.

Mediplus Pharma’s article “Ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin” was accepted into the “Journal of Cosmetic Dermatology” and used as the journal cover

Cover page of the “Journal of Cosmetic Dermatology” (USA), an international academic journal of cosmetic dermatology and human clinical sciences. Mediplus Pharma Inc. (Representative Director Kenji Ito, head office: Shibuya-ku, Tokyo) announces that the article on Mediplus Pharma’s patented ingredient: ozonized glycerin titled “Ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin” was accepted into the American […]

Mediplus Pharma is presenting posters at Society for Investigative Dermatology(SID)annual meeting 2022

Mediplus Pharma, Inc. (CEO: Kenji Ito, Head Office: Shibuya-ku, Tokyo,JAPAN) made a scientific presentation at the annual meeting of the Society for Investigative Dermatology (May 18-21, 2022, Portland, USA), which is considered the world’s highest-level society in dermatological research. Title:Novel glycerin compounds improve skin health